Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

JAK inhibitors can be safely used in alopecia areata patients with latent hepatitis B or tuberculosis, with proper monitoring.

Baricitinib helps regrow hair in teens with severe alopecia areata.

Baricitinib for severe alopecia areata is generally safe, with common side effects like infections and acne, and low rates of serious complications.

Ritlecitinib is a new treatment for severe hair loss in people 12 and older.

Baricitinib helps keep hair, eyebrows, and eyelashes regrown for 3 years in most people with severe hair loss.

Baricitinib helped treat a man's beard hair loss when steroids didn't work.

Erlotinib can cause unusual hair growth, like long eyelashes and facial hair.

The FDA approved Litfulo® for treating severe alopecia areata in people aged 12 and older.

Upadacitinib improved both Crohn's ileitis and alopecia universalis in a patient.

Ruxolitinib can help regrow hair in severe alopecia areata.

Baricitinib was effective in regrowing eyebrow and eyelash hair in patients with severe alopecia areata.

Upadacitinib successfully treated a child's severe skin and hair loss issues.

Baricitinib is effective and safe for treating alopecia areata in Korea.

Ruxolitinib and tofacitinib are effective and safe for treating severe alopecia areata.

Baricitinib helped most teenagers with severe hair loss regrow hair and had mild side effects.

Baricitinib helps long-term hair regrowth in severe alopecia areata patients.

Baricitinib effectively promotes beard regrowth in most men with alopecia areata universalis.

A patient with Alopecia Areata had complete hair regrowth after using the drug baricitinib.

The FDA approved a new Pfizer drug for hair loss in teens.

Baricitinib effectively promotes hair regrowth in severe alopecia with minimal side effects.

Baricitinib is the most effective treatment for alopecia areata.

Baricitinib may effectively treat both alopecia areata and immune thrombocytopenia.

Baricitinib is an effective treatment for severe alopecia areata.

Gefitinib can cause skin problems, diarrhea, and nausea, but rarely causes severe lung disease or hair loss.

Imatinib can repigment grey hair, while SU11428 can cause temporary hair depigmentation.

Baricitinib slightly increased cholesterol levels in alopecia areata patients, but these changes were manageable.

BI 2536 had limited effectiveness against several advanced cancers and caused significant side effects.

Ruxolitinib effectively regrows hair in most patients with severe hair loss.

Baricitinib effectively treats alopecia areata, with over half of patients improving after 52 weeks.

BAY 43-9006 helps control kidney cancer growth but doesn't significantly increase overall survival.